November 2008 - Page 72 of 76

MondayNov 03, 2008 4:11 am

Amarin Corporation plc (NASDAQ: AMRN)

Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company, has a lead program entering Phase 3 for hypertriglyceridemia. The company’s cardiovascular programs take advantage of the staff’s expertise in the field of lipid science and the acknowledged therapeutic benefits of essential fatty acids in cardiovascular disease. In addition to Amarin’s lead program, their pipeline includes programs in myasthenia gravis, Huntington’s disease, Parkinson’s disease and epilepsy. For further information, visit the Company's web site at www.amarincorp.com.

MondayNov 03, 2008 4:11 am

Midnight Oil Exploration Ltd. (TSX: MOX CN)

Midnight Oil Exploration Ltd. (TSX: MOX CN), a top quality junior exploration and production company, focuses on selected multi-zone, high-potential areas of the Western Canadian Sedimentary Basin. The company has a high-end technical team with experience, expertise, and innovative business execution skills that provide a competitive edge. Midnight's investment strategy is driven by a risk-balanced portfolio of high-potential exploration and development prospects and strategic acquisitions. For further information, visit the Company's web site at www.midnightoil.ca.

MondayNov 03, 2008 4:10 am

MiddleBrook Pharmaceuticals, Inc. (NASDAQ: MBRK)

MiddleBrook Pharmaceuticals, Inc. (NASDAQ: MBRK), a pharmaceutical company, is focused on developing and commercializing anti-infective drug products that address unmet medical needs in anti-infective therapy. The company’s aim is to develop a portfolio of drugs based on their biological finding that bacteria are killed more efficiently and effectively when exposed to antibiotics in front-loaded, sequential bursts, or pulses, than those exposed to standard antibiotic treatment regimens. For further information, visit the Company's web site at www.middlebrookpharma.com.

MondayNov 03, 2008 4:09 am

Metabasis Therapeutics, Inc. (NASDAQ: MBRX)

Metabasis Therapeutics, Inc. (NASDAQ: MBRX), a biopharmaceutical company, focuses their efforts on discovering, developing and commercializing innovative drugs by applying its scientific expertise, proprietary technologies and unique capabilities for targeting the liver and liver pathways. The company has established advanced research programs and a broad pipeline of product candidates, all of which were developed through the leveraging of their proprietary technologies. For further information, visit the Company's web site at www.mbasis.com.

MondayNov 03, 2008 4:09 am

Memory Pharmaceuticals Corp. (NASDAQ: MEMY)

Memory Pharmaceuticals Corp. (NASDAQ: MEMY) is a biopharmaceutical company focused on developing novel drugs designed to treat debilitating central nervous system (CNS) disorders, many of which significantly impair memory and other cognitive function. The company utilizes their staff’s expertise of the neuronal pathways involved in memory formation and cognition to identify highly relevant targets. By using in-house expertise in drug discovery and development, Memory Pharmaceuticals has generated a diverse pipeline of promising drug development programs. For further information, visit the Company's web site at www.memorypharma.com.

MondayNov 03, 2008 4:08 am

MediciNova, Inc. (NASDAQ: MNOV)

MediciNova, Inc. (NASDAQ: MNOV), a biopharmaceutical company, is dedicated to acquiring and developing innovative, small-molecule therapeutics designed to treat diseases with medical needs that are currently unmet. By strategically forming alliances with other pharmaceutical companies, the company holds rights to a diversified portfolio of clinical and preclinical product candidates. MediciNova believes each of these candidates has a well-characterized and unique therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. For further information, visit the Company's web site at www.medicinova.com.

MondayNov 03, 2008 4:07 am

Maxygen, Inc. (NASDAQ: MAXY)

Maxygen, Inc. (NASDAQ: MAXY) was founded with the purpose of developing important commercial products by leveraging biotechnology. Since then, the company has established a pipeline of product candidates that address unmet medical needs. Maxygen’s key protein pharmaceutical programs include: MAXY-G34 , an improved G-CSF protein to treat neutropenia; MAXY-VII , an improved factor VIIa protein to treat hemophilia; and MAXY-4 , an improved CTLA4-Ig protein to treat rheumatoid arthritis. For further information, visit the Company's web site at www.maxygen.com.

MondayNov 03, 2008 4:07 am

Marifil Mines Ltd. (TSX: MNKD)

Marifil Mines Ltd. (TSX: MFM CN), a Canadian resource exploration company is focused on aggressively exploring for precious and base metals in Argentina, home of some of the world's most prolific recent discoveries. The Company has built a remarkable portfolio of approximately 20 properties, including several showing bonanza grade gold and silver values. Marifil strategically enhances its properties through focused exploration and drilling, and then utilizes joint ventures with other mining companies to build greater shareholder value. For further information, visit the Company's web site at www.marifilmines.com.

MondayNov 03, 2008 4:06 am

Alyst Acquisition Corporation (AMEX: AYA

Alyst Acquisition Corporation (AMEX: AYA) was incorporated in August of 2006 for the purpose of raising capital from the public equity markets and using the capital to effectuate a merger, capital stock exchange, asset acquisition or other similar business combination. Since the young company’s IPO in June of 2007, Alyst has raised over $64 million and have recently announced a plan of merger with China Networks Media, Ltd. For further information, visit the company website at: www.alyst.net.

MondayNov 03, 2008 4:06 am

MannKind Corporation (NASDAQ: MNKD)

MannKind Corporation (NASDAQ: MNKD), a biopharmaceutical company, has focused their efforts on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Technosphere® Insulin System, the company’s lead investigational product candidate, is currently in Phase 3 clinical trials in the U.S., Europe and Latin America. MannKind believes the Technosphere® Insulin System has the potential to revolutionize the way diabetes is treated. For further information, visit the Company's web site at www.mannkindcorp.com.

Site Search

Company Search

Month: November 2008